Management of breast cancer brain metastases: Focus on human epidermal growth factor receptor 2-positive breast cancer
After the introduction of trastuzumab, a monoclonal antibody that binds to human epidermal growth factor receptor 2 (HER2), the overall survival (OS) among patients with HER2-positive breast cancer has been substantially improved. However, among these patients, the incidence of brain metastases (BM)...
Enregistré dans:
Auteurs principaux: | Peng Yuan, Song-Lin Gao |
---|---|
Format: | article |
Langue: | EN |
Publié: |
KeAi Communications Co., Ltd.
2017
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/b7d0348f3a6843e9a2eea76808764af7 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Use of comorbidity indices in patients with any cancer, breast cancer, and human epidermal growth factor receptor-2-positive breast cancer: A systematic review.
par: Maribel Salas, et autres
Publié: (2021) -
Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer
par: Yardley DA
Publié: (2016) -
Erlotinib eradicates brain metastases from epidermal growth factor receptor mutant non-small cell lung cancer
par: Siavash Jabbari, et autres
Publié: (2011) -
Optimal management of bone metastases in breast cancer patients
par: Wong MH, et autres
Publié: (2011) -
Emerging role of brain metastases in the prognosis of breast cancer patients
par: Hambrecht A, et autres
Publié: (2011)